


# Cell Therapy Services

**>> Request starting material for your scientific study from our donors**

As just one example a recent study conducted by City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the US, explored the adoptive transfer of SARS-CoV-2-specific T-cell immunity through allogeneic hematopoietic stem cell transplantation (HSCT). Using **data and cell material from DKMS-registered volunteer donors** – who provided informed consent – the researchers tracked a couple of patient/donor pairs in which vaccinated unrelated donors provided grafts to immunocompromised recipients.



**The key finding:** Donor-derived, virus-specific T cells successfully engrafted, expanded, and contributed to early immune protection in the recipients, even in patients who had not been vaccinated prior to their stem cell transplantation. This study demonstrates that **donor vaccination history** and immune profiling **can play an essential role in enhancing recovery in COVID-19 patients** following stem cell transplantation, offering valuable insights for improving clinical decision-making and patient outcomes.

Full publication via DOI: [10.1002/qjh.26691](https://doi.org/10.1002/qjh.26691)

This collaboration also shows how organizations like **DKMS** can **meaningfully contribute to cutting-edge academic and clinical research** through their **rigorous donor engagement and data infrastructure**. Our colleagues serve as the **vital link between stem cell donors and research sponsors** – enabling studies that advance knowledge and improve patient outcomes.

**Turn the page to find out more** on how DKMS can support similar studies by offering access to high-resolution HLA-typed donors, immune characterization, and regulated GMP-compliant cell collection.




## Together, we revolutionize blood cancer treatment

Our Cell Therapy Services working group is the point of contact for any institution seeking **HLA-compatible donor derived starting material** to manufacture Advanced Therapy Medicinal Products (ATMP) **for clinical trials or for approved drugs**. Additionally you can **request DKMS donors for your study** and our Clinical Trials Unit will guide you through the processes.

### Our tasks

As part of our strong commitment to scientific research, DKMS actively **supports both clinical and non-clinical research projects** that require **donor blood or stem cells of our volunteer donors** by combining the unique and diverse expertise across the entire organization. Many of these studies are focused on developing innovative strategies to prevent or treat post-transplant complications such as graft-versus-host disease (GvHD), viral infections, and disease relapse. We ensure **full regulatory compliance**, including obtaining **ethical approvals** and **drafting or translating donor informed consent documentation**, as required.

We invite you to **collaborate with us in the field of ATMPs** and benefit from access to our comprehensive **range of expertise and resources across the entire process**:



**DKMS** Group gGmbH  
Cell Therapy Services  
Aachener Str. 1042, 50858 Köln, Germany  
Clinical Trials Unit  
Augsburger Straße 3, 01309 Dresden, Germany

Our organization is dedicated to the fight against blood cancer and blood disorders by:

- creating **awareness** for the topic,
- **recruiting** hematopoietic stem cell donors to provide **a second chance at life**,
- **raising funds** to match donor registration costs, and
- supporting the **improvement** of blood cancer therapies **via our own research**.

### Contact

celltherapyservices@dkmsgroup.org  
+49 221 94 05 82 3451

### More information



professional.dkms.org